Recognizing encephalopathy in immune checkpoint inhibitor therapy: A single‐center experience

BACKGROUND: In this pilot study, we examined the characteristics of patients with and without central nervous system (CNS) malignancies who developed immune checkpoint inhibitor (ICI)‐induced encephalopathy. METHODS: We identified adult patients treated with ICIs between 1 January 2013 and 9 May 201...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Danmeng, Zhou, Daniel J., Datta, Proleta, Taraschenko, Olga
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085930/
https://www.ncbi.nlm.nih.gov/pubmed/33660430
http://dx.doi.org/10.1002/cam4.3818

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085930/
https://www.ncbi.nlm.nih.gov/pubmed/33660430
http://dx.doi.org/10.1002/cam4.3818

Ejemplares similares